Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vemurafenib in BRAF V600+ Papillary Thyroid Cancer
NCT01286753Phase 2Completed
- Sponsor
- Roche
- Start
- Jun 2011
- Primary completion
- Nov 2014
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 2 trial of vemurafenib in papillary thyroid cancer (PTC), sponsored by Roche. Started Jun 2011; status: completed.
02
Drugs
vemurafenib
03
Conditions
papillary thyroid cancer (PTC)
Beyond the preview
Go deeper on NCT01286753.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01286753.